一个更新的GLP-1受体激动剂专利审查 (2020年至今)
Weiwen Lu1,2, Zhongbo Zhou1, Neng Jiang2
1School of Pharmacy, Youjiang Medical University for Nationalities, Baise, Guangxi, PR China.
Expert opinion on therapeutic patents
|October 23, 2023
概括
新的专利重点是针对2型糖尿病和肥胖症的高级葡萄糖类-1受体激动剂 (GLP-1RAs). 这些创新包括口服配方和多激素治疗,以提高减肥和治疗效果.
科学领域:
- 药理学和药物开发领域
- 代谢疾病 代谢疾病
- 医学的知识产权在医学中的知识产权
背景情况:
- 2型糖尿病 (T2DM) 和肥胖症是全球主要的健康挑战,需要新的,有效的和持久的药物疗法.
- 葡萄糖类-1受体激动剂 (GLP-1RAs) 已被确立为T2DM,人们对其抗肥胖潜力越来越感兴趣.
研究的目的:
- 对基于新型GLP-1受体激动剂 (GLP-1RA) 的疗法审查最近的专利 (2020年1月至2023年7月).
- 确定GLP-1RAs开发中的关键趋势和创新,用于治疗糖尿病和肥胖症.
主要方法:
- 使用PATENTSCOPE数据库进行了全面的专利搜索.
- 使用的关键词包括GLP-1,GLP-1/GIP,GLP-1/GCG和GLP-1/GCG/GIP.
- 专注于与修改GLP-1RAs,小分子GLP-1RAs,多激动剂,融合蛋白和组合疗法相关的专利.
主要成果:
- 最近的专利优先考虑了GLP-1RA药物的口服和增强体重减轻.
- 开发工作集中在基于GLP-1R的多抗体,口服GLP-1RA和组合疗法.
- 这些专利涵盖了修改过的GLP-1RA,小分子类似物,多激动剂,融合蛋白和组合治疗.
结论:
- 新兴的GLP-1RA专利策略旨在通过多途径向和减少副作用来提高有效性.
- GLP-1药物的未来市场潜力将由新用途,口服配方和长效制剂的创新形成.
- 专利格局表明,强烈关注促进GLP-1RA治疗方法,用于糖尿病和肥胖管理.
相关概念视频
Glucagon-like Receptor Agonists
334
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
334
Oral Hypoglycemic Agents: Glinides
160
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
160
Dipeptidyl Peptidase 4 Inhibitors
192
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
192
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
184
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
184
Oral Hypoglycemic Agents: Biguanides and Glitazones
212
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
212
Glucose Transporters
22.8K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
22.8K


